• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Theses
  • Research Data
  • Projects
  • Organizations
  • Researchers
  • More
  • Collections
  • Statistics
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Pharmacotherapy in the Management of Anxiety and Pain During Acute Coronary Syndromes and the Risk of Developing Symptoms of Posttraumatic Stress Disorder
 

Pharmacotherapy in the Management of Anxiety and Pain During Acute Coronary Syndromes and the Risk of Developing Symptoms of Posttraumatic Stress Disorder

Options
  • Details
  • Files
BORIS DOI
10.48350/153275
Publisher DOI
10.1161/JAHA.120.018762
PubMed ID
33432839
Description
BACKGROUND: Benzodiazepines and morphine are given during acute coronary syndromes (ACSs) to alleviate anxiety and pain,
and β-blockers may also reduce pain. ACS may induce posttraumatic stress disorder (PTSD) symptoms (PTSS). When taken
during trauma other than ACS, benzodiazepines increase the risk of PTSS, but it is unknown if benzodiazepines increase the
risk of PTSS in ACS. We examined the effects of drug exposure during ACS on the development of PTSS.
METHODS AND RESULTS: Study participants were 154 patients with a verified ACS. Baseline demographics, clinical variables,
and psychological measures were obtained through a medical history, through a psychometric assessment, and from patient
records, and used as covariates in linear regression analysis. Three months after ACS, the severity of PTSS was assessed with
the Clinician-Administered PTSD Scale. During ACS, 37.7% of patients were exposed to benzodiazepines, whereas 72.1%
were exposed to morphine and 88.3% were exposed to β-blockers, but only 7.1% were exposed to antidepressants. Eighteen
(11.7%) patients developed clinical PTSD. Adjusting for all covariates, benzodiazepine use was significantly associated with
the Clinician-Administered PTSD Scale total severity score (unstandardized coefficient B [SE], 0.589 [0.274]; partial r=0.18;
P=0.032) and the reexperiencing subscore (B [SE], 0.433 [0.217]; partial r=0.17; P=0.047). Patients exposed to benzodiazepines
had an almost 4-fold increased relative risk of developing clinical PTSD, adjusting for acute stress disorder symptoms
(odds ratio, 3.75; 95% CI, 1.31–10.77). Morphine, β-blockers, and antidepressants showed no predictive value.
CONCLUSIONS: Notwithstanding short-term antianxiety effects during ACS, benzodiazepine use might increase the risk of ACSinduced
PTSS with clinical significance, thereby compromising patients’ quality of life and prognosis.
Date of Publication
2021
Publication Type
Article
Subject(s)
100 Philosophy > 150 Psychology
600 Technology > 610 Medicine & health
Language(s)
en
Contributor(s)
von Känel, Roland
Schmid, Jean‐Paul
Meister‐Langraf, Rebecca E.
Barth, Jürgen
Znoj, Hans Jörgorcid-logo
Institut für Psychologie, Abt. Gesundheitspsychologie und Verhaltensmedizin
Schnyder, Ulrich
Princip, Mary
Pazhenkottil, Aju P.
Additional Credits
Institut für Psychologie, Abt. Gesundheitspsychologie und Verhaltensmedizin
Series
Journal of the American Heart Association
Publisher
American Heart Association
ISSN
2047-9980
Access(Rights)
open.access
Show full item
BORIS Portal
Bern Open Repository and Information System
Build: dd892c [ 9.04. 8:30]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
  • Audiovisual Material
  • Software & other digital items
  • Events
More
  • About BORIS Portal
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo